A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study.
暂无分享,去创建一个
K. Weber | M. Rezai | P. Fasching | A. Schneeweiss | C. Denkert | H. Tesch | S. Loibl | K. Weber | N. Burchardi | M. Untch | J. Blohmer | S. Kümmel | G. von Minckwitz | J. Huober | J. Furlanetto | W. Schmitt | K. Engels | C. Jackisch | C. Hanusch | E. Grischke | K. Rhiem | G. Minckwitz | P. Fasching | J. Thomalla | B. Rautenberg | B. Sinn | C. Denkert | S. Loibl | M. Untch | N. Burchardi | J. Huober | B.V. Sinn | J.-U. Blohmer | E.-M. Grischke | J. Furlanetto | H. Tesch | C. Hanusch | K. Engels | M. Rezai | C. Jackisch | W.D. Schmitt | G. von Minckwitz | J. Thomalla | S. Kümmel | B. Rautenberg | P.A. Fasching | K. Rhiem | A. Schneeweiss | C. Hanusch | C. Denkert | Jörg Thomalla
[1] F. Giles,et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) , 2018, Journal of Immunotherapy for Cancer.
[2] S. Adams,et al. Checkpoint inhibitors in triple‐negative breast cancer (TNBC): Where to go from here , 2018, Cancer.
[3] E. Elgabry,et al. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study , 2019, JAMA oncology.
[4] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] S. Demaria,et al. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC) , 2015, Oncoimmunology.
[6] A. Schneeweiss,et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. , 2016, The Lancet. Oncology.
[7] P. Fasching,et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial , 2017, JAMA oncology.
[8] Carsten Denkert,et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group , 2016, Modern Pathology.
[9] S. Cannistra,et al. Phase II trials in journal of clinical oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Adams,et al. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial , 2019, JAMA oncology.
[11] L. Gianni,et al. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial , 2018, JAMA oncology.
[12] Carsten Denkert,et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Rezai,et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.
[14] P. Fasching,et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.
[15] W. Symmans,et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. , 2018, The Lancet. Oncology.
[16] P. Fasching,et al. Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69 , 2018 .
[17] Tarek Mekhail,et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[18] Donald A. Berry,et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. , 2017 .
[19] S. Baxi,et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis , 2018, British Medical Journal.
[20] Nicholas J. Vogelzang,et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study , 2017, JAMA oncology.
[21] E. Winer,et al. Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.